Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells

Toshihiko Hashimoto, Minako Imamura, Takashi Etoh, Naotaka Sekiguchi, Mitsunori Masakado, Toyoshi Inoguchi, Hajime Nawata, Fumio Umeda

    Research output: Contribution to journalArticle

    6 Citations (Scopus)

    Abstract

    We have cloned a prostacyclin (PGI2) stimulating factor (PSF), which stimulates PGI2 production by vascular endothelial cells. Previous study demonstrated the reduced PSF expression in the coronary arteries from the patients with ischemic heart disease. To clarify the mechanism of reduced PSF expression in atherosclerosis, we examined the effect of lysophosphatidylcholine (lysoPC), a main component of oxidized low density lipoprotein (LDL), on PSF expression in cultured vascular smooth muscle cells. LysoPC reduced PSF expression dose-dependently. Whereas neither phosphatidylcholine nor native LDL affects the PSF expression. Calphostin C, a protein kinase C (PKC) inhibitor, restored the reduction of PSF expression by lysoPC. These results suggest that lysoPC-induced reduction of PSF expression is mediated by PKC activation and is playing a role in the initiation and progression of atherosclerotic lesions.

    Original languageEnglish
    Pages (from-to)81-86
    Number of pages6
    JournalJournal of Diabetes and Its Complications
    Volume16
    Issue number1
    DOIs
    Publication statusPublished - Mar 5 2002

    Fingerprint

    Lysophosphatidylcholines
    Epoprostenol
    Vascular Smooth Muscle
    Smooth Muscle Myocytes
    Protein Kinase C
    Protein C Inhibitor
    Protein Kinase Inhibitors
    Phosphatidylcholines
    LDL Lipoproteins
    Myocardial Ischemia
    Atherosclerosis
    Coronary Vessels
    Endothelial Cells

    All Science Journal Classification (ASJC) codes

    • Internal Medicine
    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Cite this

    Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells. / Hashimoto, Toshihiko; Imamura, Minako; Etoh, Takashi; Sekiguchi, Naotaka; Masakado, Mitsunori; Inoguchi, Toyoshi; Nawata, Hajime; Umeda, Fumio.

    In: Journal of Diabetes and Its Complications, Vol. 16, No. 1, 05.03.2002, p. 81-86.

    Research output: Contribution to journalArticle

    Hashimoto, Toshihiko ; Imamura, Minako ; Etoh, Takashi ; Sekiguchi, Naotaka ; Masakado, Mitsunori ; Inoguchi, Toyoshi ; Nawata, Hajime ; Umeda, Fumio. / Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells. In: Journal of Diabetes and Its Complications. 2002 ; Vol. 16, No. 1. pp. 81-86.
    @article{ffe95196204c4ca8811da96cd3e523ab,
    title = "Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells",
    abstract = "We have cloned a prostacyclin (PGI2) stimulating factor (PSF), which stimulates PGI2 production by vascular endothelial cells. Previous study demonstrated the reduced PSF expression in the coronary arteries from the patients with ischemic heart disease. To clarify the mechanism of reduced PSF expression in atherosclerosis, we examined the effect of lysophosphatidylcholine (lysoPC), a main component of oxidized low density lipoprotein (LDL), on PSF expression in cultured vascular smooth muscle cells. LysoPC reduced PSF expression dose-dependently. Whereas neither phosphatidylcholine nor native LDL affects the PSF expression. Calphostin C, a protein kinase C (PKC) inhibitor, restored the reduction of PSF expression by lysoPC. These results suggest that lysoPC-induced reduction of PSF expression is mediated by PKC activation and is playing a role in the initiation and progression of atherosclerotic lesions.",
    author = "Toshihiko Hashimoto and Minako Imamura and Takashi Etoh and Naotaka Sekiguchi and Mitsunori Masakado and Toyoshi Inoguchi and Hajime Nawata and Fumio Umeda",
    year = "2002",
    month = "3",
    day = "5",
    doi = "10.1016/S1056-8727(01)00211-2",
    language = "English",
    volume = "16",
    pages = "81--86",
    journal = "Journal of Diabetes and its Complications",
    issn = "1056-8727",
    publisher = "Elsevier Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells

    AU - Hashimoto, Toshihiko

    AU - Imamura, Minako

    AU - Etoh, Takashi

    AU - Sekiguchi, Naotaka

    AU - Masakado, Mitsunori

    AU - Inoguchi, Toyoshi

    AU - Nawata, Hajime

    AU - Umeda, Fumio

    PY - 2002/3/5

    Y1 - 2002/3/5

    N2 - We have cloned a prostacyclin (PGI2) stimulating factor (PSF), which stimulates PGI2 production by vascular endothelial cells. Previous study demonstrated the reduced PSF expression in the coronary arteries from the patients with ischemic heart disease. To clarify the mechanism of reduced PSF expression in atherosclerosis, we examined the effect of lysophosphatidylcholine (lysoPC), a main component of oxidized low density lipoprotein (LDL), on PSF expression in cultured vascular smooth muscle cells. LysoPC reduced PSF expression dose-dependently. Whereas neither phosphatidylcholine nor native LDL affects the PSF expression. Calphostin C, a protein kinase C (PKC) inhibitor, restored the reduction of PSF expression by lysoPC. These results suggest that lysoPC-induced reduction of PSF expression is mediated by PKC activation and is playing a role in the initiation and progression of atherosclerotic lesions.

    AB - We have cloned a prostacyclin (PGI2) stimulating factor (PSF), which stimulates PGI2 production by vascular endothelial cells. Previous study demonstrated the reduced PSF expression in the coronary arteries from the patients with ischemic heart disease. To clarify the mechanism of reduced PSF expression in atherosclerosis, we examined the effect of lysophosphatidylcholine (lysoPC), a main component of oxidized low density lipoprotein (LDL), on PSF expression in cultured vascular smooth muscle cells. LysoPC reduced PSF expression dose-dependently. Whereas neither phosphatidylcholine nor native LDL affects the PSF expression. Calphostin C, a protein kinase C (PKC) inhibitor, restored the reduction of PSF expression by lysoPC. These results suggest that lysoPC-induced reduction of PSF expression is mediated by PKC activation and is playing a role in the initiation and progression of atherosclerotic lesions.

    UR - http://www.scopus.com/inward/record.url?scp=0036179040&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0036179040&partnerID=8YFLogxK

    U2 - 10.1016/S1056-8727(01)00211-2

    DO - 10.1016/S1056-8727(01)00211-2

    M3 - Article

    C2 - 11872373

    AN - SCOPUS:0036179040

    VL - 16

    SP - 81

    EP - 86

    JO - Journal of Diabetes and its Complications

    JF - Journal of Diabetes and its Complications

    SN - 1056-8727

    IS - 1

    ER -